CYP17A1 and prostate carcinoma: Although the FDA-approved drug abiraterone acetate used as the CYP17 inhibitor for the treatment of metastatic prostate cancer [32,49], still there is much ongoing research on prostate cancer towards development of newer anticancer drug entities against this important drug target.